Member Info for Sp28

Closed loop healthcare model.

I don’t think most have not even grasped the size of the opportunity here, and what they are creating, with a clear MOAT and competitive advantages, pretty unique.

1. AI triage (Juno)

2. GP consultations

3. Prescribing

4. Robotic pharmacy dispensing

5. Medication delivery

6. Follow-up monitoring

You can say Amazon of healthcare again!!

Institutions and PE will start buying in here.

Millions of people could qualify under NICE obesity-drug criteria, and there is growing evidence, there are numerous other uses for eg Cardiovascular disease, Fatty liver disease (MASH), Addiction treatment, Neurodegenerative diseases. GLP-1 drugs could become one of the most broadly used drug classes in modern medicine.

Market opportunity is enormous. That is why companies such as Novo Nordisk⁠ and Eli Lilly⁠ have become some of the most valuable pharmaceutical companies in the world. Investors are not valuing them as “weight-loss companies”; they are valuing them as companies potentially reshaping multiple trillion-dollar healthcare categories.

For MPAL, GLP-1 is a big avenue to providing full healthcare provision for all their needs as a patient.

RECURRING WEEKLY/MONTHLY revenue!

Absolutely no doubt MPAL will race away.

Market opportunity is insanely massive AI/Weight loss/Health , and a very small number of shares, the perfect storm for a rapid rise.

✅ AI/Health/Weight loss Industry - Holy Trinity

✅ UK, launched in Germany recently, US identified as a major market

✅ Wegovy pill approved for use in UK by MHRA

✅ Wegovy pill pending NICE approval, currently in assesment

✅ Wegovy pill in the US - One of the strongest pharmaceutical launches on record!!!

✅ MPAL has direct supply agreements with Eli Lilly and Novo Nordisk

✅ Revenues are scaling rapidly

✅ Last week MPAL launched: 24-7 AI GP and Pharmacy into a single service - Juno

✅ Free float is tiny with high BOD and institutional ownership: 65%-70%

✅ Conservative broker targets of 30p & 42p, and a high of 112p!

✅ Fully cashed up - raised £3m on 17/04/26

Always DYOR

Juno could be a company-defining launch, transforming MedPal from a pharmacy business into an AI-powered healthcare platform.

Every Juno user can be seamlessly connected to MedPal’s clinicians, prescriptions and pharmacy services, creating multiple revenue opportunities per patient.

Repeat demand and repeat revenue, better than a gold mine.

Closed loop healthcare model.

I don’t think most have not even grasped the size of the opportunity here, and what they are creating, with a clear MOAT and competitive advantages, pretty unique.

1. AI triage (Juno)

2. GP consultations

3. Prescribing

4. Robotic pharmacy dispensing

5. Medication delivery

6. Follow-up monitoring

You can say Amazon of healthcare again!!

Institutions and PE will start buying in here.

A recap of a unique opportunity...

Once profitability is confirmed, we could see a hocky stick style rise here.

✅ AI/Health/Weight loss Industry - Holy Trinity

✅ UK, launched in Germany recently, US identified as a major market

✅ Wegovy pill approved for use in UK by MHRA

✅ Wegovy pill pending NICE approval, currently in assesment

✅ Wegovy pill in the US - One of the strongest pharmaceutical launches on record!!!

✅ MPAL has direct supply agreements with Eli Lilly and Novo Nordisk

✅ Revenues are scaling rapidly

✅ Last week MPAL launched: 24-7 AI GP and Pharmacy into a single service - Juno

✅ Free float is tiny with high BOD and institutional ownership: 65%-70%

✅ Conservative broker targets of 30p & 42p, and a high of 112p!

✅ Fully cashed up - raised £3m on 17/04/26

Always DYOR

Https://www.cbc.ca/news/health/glp1-health-benefits-cancer-prevention-second-opinion-9.7241872?__vfz=medium%3Dsharebar

This was 5.5p on Monday at the back of the Wegovy approval.

We then had the following RNS:

https://www.investegate.co.uk/announcement/rns/medpal-ai-plc--mpal/launch-of-juno-medpal-s-ai-health-companion/9624094

Many will be kicking themselve as this races back to 10-15p for starters, free float is very very tight, supply and demand! Very small supply of shares, huge demand, only means one thing!

MPAL are in the AI, Health and Weight Loss sectors, all booming and in high demand. And they can in time replicate the success internationally.

Transfer from impatient traders to patient investors.

From last weeks rise, most will have been washed out.

This should already be double digits.

Don’t forget 2 Blockbuster RNS’s in the last 5 days.

This is a solution badly needed.

Everyone knows, the UK national GP and health service is totally broken.

Would not be surprised with NHS contracts coming their way to ease some of the burden.

This is massive, market opportunity is extraordinary.

MedPal AI can genuinely become a unicorn! Never said that before 😉

Genuinely, if this was listed in the US, it would be worth 10x more already.

This was 5.5p at the beginning of this week, and we've had another positive RNS since.

@solo1

Currently under NICE evaluation…

“NICE first planned to assess oral semaglutide for weight management in 2022, then discontinued that appraisal in 2025 after Novo Nordisk didn’t submit evidence at the time.

Now that the pill is approved, NICE has reopened that assessment, which is the step that decides NHS funding”

✅ AI/Health/Weight loss Industry - Holy Trinity

✅ UK, launched in Germany recently, US identified as a major market

✅ Wegovy pill approved for use in UK by MHRA

✅ Wegovy pill pending NICE approval

✅ Wegovy pill in the US - One of the strongest pharmaceutical launches on record

✅ MPAL has direct supply agreements with Eli Lilly and Novo Nordisk

✅ Revenues are scaling rapidly

✅ Yesterday launched a 24-7 AI GP and Pharmacy into a single service - Juno

✅ Free float is tiny with high BOD and institutional ownership

✅ Conservative broker targets of 30p & 42p, and a high of 112p!

✅ Fully cashed up - raised £3m on 17/04/26

DYOR

“For the clinic/GLP-1 side, this is where the direct supply agreements with Eli Lilly (Mounjaro) and Novo Nordisk (Wegovy) are critical. These give Medpal allocation certainty that competitors relying on wholesale channels don’t have.” 👊

https://www.clearcapitalmarkets.co.uk/analysis/medpal-ai-broker-note

Https://www.prnewswire.com/news-releases/wegovy-pill-prescriptions-surpass-3-million-1-filled-roughly-every-5-seconds-bringing-glp-1-therapy-to-people-with-obesity-previously-untreated-while-novo-nordisk-unveils-new-data-at-ada-2026-302793337.html

Just shows the incredible market opportunity.

“One of the strongest US pharmaceutical launches by volume on record” 🤯

500k and 593k buys just now, hoovering up whatever is left of this small free float

A solution badly needed.

Everyone knows, the UK national GP and health service is totally broken.

Would not be surprised with NHS contracts coming their way to ease some of the burden.

This is massive, market opportunity is extraordinary.

MedPal AI can genuinely become a unicorn! Never said that before 😉

Another transformational RNS.

Market opportunity is truly mind boggling.

Can see where the clear capital top end price target of 112p comes from.

They just need a small crumb from a MASSIVE market.

You mean 4.4p - 4.8p ish open ish 👊

Https://www.theguardian.com/science/2026/jun/02/weight-loss-drugs-cut-cancer-risk-studies?CMP=share_btn_url

Transformational just in the weight loss space, this could be much much bigger